AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24460975
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (15 ml) deposited below the femoral nerve (Group B)
Trial: 24460975
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (15 ml) deposited circumferential to the femoral nerve (Group C)
Trial: 24463454
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg) single dose
Trial: 24463454
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg) chronic treatment
Trial: 24464121
Drug: Stabilized hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stabilized hyaluronic acid gel (HA)
Trial: 24464355
Drug: Pazopanib 400
RxNorm normalized name: PAZOPanib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 400 mg/day on day 1 followed by 800 mg/day from day 2 onward
Trial: 24464355
Drug: Pazopanib 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 1,000 mg/day
Trial: 24464355
Drug: Pazopanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib plus lapatinib (400/1,000 mg, 800/1,000 mg, 400/1,500 mg, 600/1,250 mg)
Trial: 24464355
Drug: Pazopanib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib monotherapy (800 mg and 1,000 mg) and pazopanib plus lapatinib (any doses)
Trial: 24465046
Drug: 2.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 µg sufentanil plus 0.5% levobupivacaine (2.2 ± 0.2 mL)
Trial: 24465046
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg fentanyl plus 0.5% levobupivacaine (2.2 ± 0.2 mL)
Trial: 24465046
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine (2.2 ± 0.2 mL)
Trial: 24467979
Drug: Interleukin-10 treatment
RxNorm normalized name: interleukin-10
DrugBank: Interleukin-10 (DB12880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-10 treatment
Trial: 24467987
Drug: Stool substitute
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stool substitute preparation made from purified intestinal bacterial cultures derived from a single healthy donor
Trial: 24467987
Drug: Stool substitute
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stool substitute preparation
Trial: 24470004
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of 90-minute twice per week hatha yoga classes
Trial: 24473178
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy with assessment of collateral grade
Trial: 24473178
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy with robust angiographic collateral grade
Trial: 24473509
Drug: Pharmacoinvasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacoinvasive treatment (tenecteplase thrombolysis followed by percutaneous coronary intervention)
Trial: 24474568
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day) with non-ritonavir HAART
Trial: 24474568
Drug: Sunitinib (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (dose escalation from 25 mg/day to 50 mg/day) with ritonavir-based HAART
Trial: 24475922
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg once daily for 8 weeks)
Trial: 24476740
Drug: Progenitor cell
RxNorm normalized name: Human glial progenitor cells
DrugBank: Human glial progenitor cells (DB18265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progenitor cell therapy (CD34+ selected cell suspension injected into the wound)
Trial: 24476740
Drug: Sham side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham side (no progenitor cell treatment)
Trial: 24476740
Drug: Histologic analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histologic analysis after progenitor cell treatment
Trial: 24477328
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin (500 mg, once daily for 2-5 days) followed by oral azithromycin (500 mg, once daily for 7-10 days)
Trial: 24477453
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate therapy (3-h intravenous infusion aiming to increase systemic lactate to ca. 5 mmol/L)
Trial: 24477453
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate therapy
Trial: 24477603
Drug: 15.5 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15.5 mg/m2 ombrabulin
Trial: 24477603
Drug: 25 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 ombrabulin
Trial: 24477603
Drug: 35 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/m2 ombrabulin
Trial: 24477603
Drug: 50 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 ombrabulin
Trial: 24477837
Drug: Pill Placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill Placebo
Trial: 24477837
Drug: Acute Treatment
RxNorm normalized name: Acute phase reactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute Treatment Responders
Trial: 24477837
Drug: Acute Treatment
RxNorm normalized name: Acute phase reactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute Treatment Non-Responders
Trial: 24480627
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D <20 ng/ml
Trial: 24480627
Drug: parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: parathyroid hormone ≥65 pg/ml
Trial: 24480627
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D ≥30 ng/ml
Trial: 24480627
Drug: parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: parathyroid hormone <33 pg/ml
Trial: 24480824
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m² intravenously, one or two doses)
Trial: 24481953
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT) of vitamin K antagonist (VKA), aspirin, and clopidogrel
Trial: 24482099
Drug: Subcutaneous pasireotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous pasireotide 600 μg bid for 15 days
Trial: 24484064
Drug: Renal colic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal colic protocol CT with a mean dose-length product (DLP) of 746 mGy ⋅ cm (effective dose, 11.2 mSv)
Trial: 24484064
Drug: Renal colic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal colic protocol CT with reduced dose (DLP of 200 mGy ⋅ cm or lower)
Trial: 24487484
Drug: Adalimumab 24
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 24 mg/m² (maximum 20 mg/dose) every other week up to 120 weeks
Trial: 24488560
Drug: Rabbit anti-thymocyte
RxNorm normalized name: Rabbit anti-thymocyte immunoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit anti-thymocyte globulin (2.5 mg/kg/day for 4 doses)
Trial: 24488798
Drug: Midostaurin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin (25 or 50 mg orally twice daily) + all-trans retinoic acid (ATRA) + CLAG chemotherapy
Trial: 24490070
Drug: Second Generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second Generation Antipsychotics
Trial: 24491372
Drug: Daily self-monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-monitoring of peak cough expiratory flow, oxygen saturation, and respiratory discomfort
Trial: 24492296
Drug: ARGX-110 (defucosylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARGX-110 (defucosylated IgG1 monoclonal antibody)
Trial: 24493157
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg/day p.o.
Trial: 24493215
Drug: LCP-Tacro once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCP-Tacro once-daily
Trial: 24493287
Drug: Genetic targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic targeting of Cxcr2 receptor in murine model
Trial: 24493717
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg twice per day for 1 month (cohort A)
Trial: 24493717
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg twice per day for an average of 2.3 months (cohort B)
Trial: 24496920
Drug: nab-paclitaxel 60
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 60 mg/m(2) weekly + cetuximab 250 mg/m(2) weekly + IMRT (70 Gy)
Trial: 24496920
Drug: nab-paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 80 mg/m(2) weekly + cetuximab + IMRT
Trial: 24496920
Drug: nab-paclitaxel 60
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 60 mg/m(2) weekly + cetuximab + IMRT
Trial: 24497495
Drug: Antinuclear antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antinuclear antibodies (ANAs) positivity
Trial: 24497495
Drug: Anticardiolipin antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticardiolipin antibodies (aCL) positivity
Trial: 24500145
Drug: Elevated intact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated intact parathyroid hormone (PTH) (>62 pg/mL) with very low calcium intake (<60% of EAR) or insufficient 25-hydroxyvitamin D (<20 ng/mL)
Trial: 24500145
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low 25(OH)D (<12 ng/mL)
Trial: 24500145
Drug: Elevated PTH
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elevated PTH (>62 pg/mL)
Trial: 24500148
Drug: Cobalt supplement
RxNorm normalized name: Cobalt supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobalt supplement (1.0 mg Co/d) for 90 days
Trial: 24500152
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS) containing sodium selenite and antiretroviral drugs (ARV)
Trial: 24500155
Drug: Magnesium intake
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium intake >422.5 mg Mg/d
Trial: 24500940
Drug: 2 stable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 stable magnesium isotopes (∼23 mg of oral ²⁶Mg and ∼11 mg of i.v. ²⁵Mg) administered to cohort 1
Trial: 24501009
Drug: Dacomitinib (PF-00299804)
RxNorm normalized name: dacomitinib
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dacomitinib (PF-00299804) 45 mg once daily continuously in 21-day cycles
Trial: 27280802
Drug: Multilayer Flow
RxNorm normalized name: zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multilayer Flow Modulator (MFM)
Trial: 24502534
Drug: Intraarticular Botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular Botulinum toxin type A (BoNT-A) injection (100 units)
Trial: 24502534
Drug: Intraarticular hyaluronate
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular hyaluronate injection plus rehabilitation exercise (30 minutes/day, 3 times/week for 4 weeks)
Trial: 24502534
Drug: Intraarticular hyaluronate
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular hyaluronate injection plus rehabilitation exercise
Trial: 24502534
Drug: Intraarticular BoNT-A
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular BoNT-A injection
Trial: 24502608
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) optimization with echocardiography as reference
Trial: 24503265
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human recombinant interferon-beta-1a (FP-1201) at an optimal tolerated dose of 10 μg per day for 6 days
Trial: 24503265
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human recombinant interferon-beta-1a (FP-1201)
Trial: 24504509
Drug: Vaccine-induced IgG
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-induced IgG antibodies to V1V2 regions of HIV-1 subtypes A, B, C, D, or CRF01_AE.
Trial: 24504737
Drug: Lipopolysaccharide (low-dose)
RxNorm normalized name: sulfated mucopolysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipopolysaccharide (low-dose)
Trial: 24506412
Drug: Montelukast monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast monotherapy (10 mg, once daily) in leukotriene-sensitive group
Trial: 24506412
Drug: Montelukast monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast monotherapy (10 mg, once daily) in leukotriene-insensitive group
Trial: 24508104
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy based on genomic alterations identified through CGH array and Sanger sequencing.
Trial: 24508104
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy received by 43 assessable patients.
Trial: 24508570
Drug: Permacol™ surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permacol™ surgical implant
Trial: 24512954
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m² on days 1, 4, 8, and 11 of a 21-day cycle
Trial: 24516013
Drug: R (rituximab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R (rituximab) 375 mg/m(2) once per week for 4 weeks
Trial: 24516013
Drug: R +
RxNorm normalized name: Immune 24 Hour +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R + MR (rituximab plus maintenance rituximab) administered once every 6 months for 2 years
Trial: 24516026
Drug: Intravenous pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pegaspargase at 2,000 IU/m(2) per dose, administered in six doses with intervals longer than 4 weeks
Trial: 24516026
Drug: Intravenous pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pegaspargase
Trial: 24517219
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin G (IVIG) therapy (0.4 g kg(-1) day(-1) for 5 days)
Trial: 24517417
Drug: 300IR birch
RxNorm normalized name: BIRCH TRITERPENES
DrugBank: Birch bark extract (DB16536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300IR birch pollen sublingual solution
Trial: 24519196
Drug: Transdermal nanostructured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nanostructured formulation of progesterone (10%) combined with estriol (0.1%) + estradiol (0.25%)
Trial: 24519196
Drug: Transdermal nanostructured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nanostructured formulation of progesterone and estrogens
Trial: 24520093
Drug: MAGE-A3 peptide
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 peptide vaccine combined with Poly-ICLC (Hiltonol), granulocyte macrophage colony-stimulating factor (GM-CSF) ± montanide
Trial: 24520094
Drug: Vaccine containing
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine containing GD2 and GD3 (30 μg each) and OPT-821 (150 μg/m²) with β-glucan (40 mg/kg/day, 14 days on/14 days off)
Trial: 24522441
Drug: >35% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >35% of daily energy intake from fat
Trial: 24522441
Drug: Daily fiber
RxNorm normalized name: Daily Fiber Sugar-Free
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fiber intake
Trial: 24523241
Drug: Plerixafor (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (0.01 to 0.02 mg/kg, subcutaneously, twice daily for 6 months)
Trial: 24523241
Drug: Plerixafor (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (0.01 to 0.02 mg/kg, subcutaneously, twice daily for 6 months) in combination with imiquimod
Trial: 24524285
Drug: Weight-reduction program
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-reduction program including daily caloric restriction and exercise for 12 weeks
Trial: 24525446
Drug: Theophylline/corticosteroid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline/corticosteroid combination therapy
Trial: 24526575
Drug: Bortezomib plus
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib plus irinotecan (1.3 mg/m² days 1, 4, 8, 11; 125 mg/m² days 1, 8 every 21 days)
Trial: 24526575
Drug: Bortezomib alone
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib alone (as second line therapy)
Trial: 24527713
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with 25OHD status of 20 ng/mL or greater
Trial: 24527713
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with plasma 25OHD less than 20 nmol/L
Trial: 24527713
Drug: Overweight/obese subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overweight/obese subjects with 25OHD status of 20 ng/mL or greater
Trial: 24527713
Drug: Normal weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal weight subjects with 25OHD status of 20 ng/mL or greater
Trial: 24528505
Drug: Home Dialysis
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home Dialysis Virtual Ward (HDVW) intervention with weekly clinician-led telephone interviews for 2 weeks until VW discharge.
Trial: 24529163
Drug: Infliximab 3
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 3 mg/kg plus methotrexate (MTX) for 14 weeks
Trial: 24529291
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (ramipril), specific dosage and duration not mentioned.
Trial: 24530971
Drug: Fludarabine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (up to 210 mg/m2)
Trial: 24534108
Drug: 5-azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-azacitidine (75 mg/m² for 5 to 7 days every 4 weeks until a suitable donor was found)
Trial: 24534286
Drug: Low age
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low age of menarche, high levels of high-sensitivity C-reactive protein and liver enzymes, low levels of sex hormone-binding globulin
Trial: 24554062
Drug: Neoadjuvant sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant sorafenib (dose escalation cohort 1: 200 mg twice daily, cohort 2: 200/400 mg daily) plus preoperative conformal radiotherapy (50 Gy in 25 fractions)
Trial: 24557359
Drug: Midstromal implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midstromal implant of an isolated Bowman layer graft
Trial: 24558033
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose naltrexone (4.5 mg/day) for 12 weeks in adults